aTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Earnings of -$0.44 Per Share

Brokerages predict that aTyr Pharma, Inc. (NASDAQ:LIFEGet Rating) will report earnings per share of ($0.44) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for aTyr Pharma’s earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.48). aTyr Pharma reported earnings per share of ($0.64) in the same quarter last year, which would suggest a positive year-over-year growth rate of 31.3%. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that aTyr Pharma will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($1.93) to ($1.54). For the next year, analysts forecast that the business will report earnings of ($1.88) per share, with EPS estimates ranging from ($2.50) to ($1.15). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for aTyr Pharma.

aTyr Pharma (NASDAQ:LIFEGet Rating) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.10). During the same period in the prior year, the business posted ($0.51) earnings per share.

A number of research firms recently weighed in on LIFE. Piper Sandler lowered their price objective on shares of aTyr Pharma from $19.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Wednesday, May 11th. Finally, StockNews.com lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $14.86.

Shares of NASDAQ LIFE remained flat at $$3.00 during mid-day trading on Friday. The company had a trading volume of 79,316 shares, compared to its average volume of 90,696. aTyr Pharma has a 1-year low of $2.89 and a 1-year high of $13.10. The firm’s 50 day simple moving average is $4.56 and its 200 day simple moving average is $6.04. The firm has a market cap of $84.18 million, a PE ratio of -1.66 and a beta of 1.54.

Large investors have recently modified their holdings of the stock. VR Adviser LLC acquired a new stake in shares of aTyr Pharma during the 3rd quarter worth approximately $14,210,000. Tikvah Management LLC grew its stake in shares of aTyr Pharma by 10.2% during the 1st quarter. Tikvah Management LLC now owns 1,350,833 shares of the biotechnology company’s stock worth $7,227,000 after purchasing an additional 125,000 shares during the period. Vanguard Group Inc. grew its stake in shares of aTyr Pharma by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 1,139,533 shares of the biotechnology company’s stock worth $6,097,000 after purchasing an additional 26,342 shares during the period. Tang Capital Management LLC acquired a new stake in shares of aTyr Pharma during the 3rd quarter worth approximately $10,110,000. Finally, Deep Track Capital LP acquired a new stake in shares of aTyr Pharma during the 4th quarter worth approximately $8,217,000. Institutional investors own 77.96% of the company’s stock.

About aTyr Pharma (Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Featured Stories

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.